1043687-62-2Relevant academic research and scientific papers
Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity
Acker, Brad A.,Jacobsen, E. Jon,Rogers, Bruce N.,Wishka, Donn G.,Reitz, Steven C.,Piotrowski, David W.,Myers, Jason K.,Wolfe, Mark L.,Groppi, Vincent E.,Thornburgh, Bruce A.,Tinholt, Paula M.,Walters, Rodney R.,Olson, Barbara A.,Fitzgerald, Laura,Staton, Brian A.,Raub, Thomas J.,Krause, Michael,Li, Kai S.,Hoffmann, William E.,Hajos, Mihaly,Hurst, Raymond S.,Walker, Daniel P.
scheme or table, p. 3611 - 3615 (2009/05/07)
A novel α7 nAChR agonist, N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (3a, PHA-709829), has been identified for the potential treatment of cognitive deficits in schizophrenia. The compound shows potent and selective α7 in vitro activity, excellent brain penetration, good rat oral bioavailability and robust in vivo efficacy in a rat auditory sensory gating model.
